Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 144,972,000, representing a 14.6% increase from HKD 126,540,000 in the same period of 2024[3] - Gross profit for the same period was HKD 126,817,000, up from HKD 110,347,000, indicating a growth of 15.0%[3] - Profit before tax increased to HKD 21,681,000, a rise of 36.0% compared to HKD 15,939,000 in 2024[4] - Net profit for the period was HKD 17,901,000, which is a 35.5% increase from HKD 13,239,000 in the previous year[4] - Basic earnings per share rose to HKD 2.35, compared to HKD 1.74 for the same period last year, reflecting a growth of 35.0%[4] - The company reported a total comprehensive income of HKD 18,461,000 for the period, compared to HKD 14,685,000 in 2024, marking a growth of 25.5%[4] - The group recorded a net profit of HKD 17,901,000 for the six months ended September 30, 2025, compared to HKD 13,239,000 in the same period of 2024, representing a 35.5% increase[40] - Basic earnings per share for the period were HKD 2.35, up from HKD 1.74 in 2024, based on a weighted average of 762,000,000 shares[41] Revenue Breakdown - Health supplement products generated revenue of HKD 138,589,000, up from HKD 120,398,000, reflecting a growth of 15.1%[12] - Revenue from health supplement products rose by 15.1% to HKD 138,589,000, while personal care products saw a slight increase of 3.3% to HKD 5,958,000[35] - Health supplement products accounted for 95.6% of total revenue in 2025, up from 95.1% in 2024, with revenue of HKD 138,589,000[36] Assets and Liabilities - Total assets as of September 30, 2025, were HKD 201,877,000, an increase from HKD 198,722,000 as of March 31, 2025[6] - Current assets increased to HKD 162,354,000 from HKD 140,382,000, showing a growth of 15.7%[5] - Cash and cash equivalents reached HKD 82,619,000, up from HKD 78,723,000, indicating a 4.8% increase[5] - Accounts receivable increased to HKD 27,707,000 as of September 30, 2025, up from HKD 21,064,000 as of March 31, 2025[26] - The average credit period for purchases is typically 0 to 90 days, with accounts payable at HKD 2,090,000 as of September 30, 2025, compared to HKD 1,615,000 as of March 31, 2025[29] Costs and Expenses - Financing costs decreased to HKD 494,000 from HKD 562,000, a reduction of 12.1%[18] - Total tax expenses for the period were HKD 3,780,000, an increase of 40% from HKD 2,700,000 in 2024[19] - Depreciation expenses for property, plant, and equipment totaled HKD 8,640,000, an increase of 13.9% from HKD 7,584,000[22] - Sales costs increased by HKD 1,962,000 or 12.1% to HKD 18,155,000, while gross margin remained stable at 87.5% compared to 87.2% in 2024[39] Corporate Governance - The audit committee has reviewed and supervised the group's financial reporting system and internal control procedures[58] - The board of directors includes two executive directors and three independent non-executive directors, ensuring a balanced governance structure[62] - The company has complied with the corporate governance code, with the exception of the separation of roles between the chairman and CEO[55] - The company has adopted a standard code of conduct for directors regarding securities trading, with all directors confirming compliance during the period[56] - The company has not established any arrangements for directors to benefit from purchasing shares or bonds of the company or any other entity during the period[54] Strategic Initiatives - The company plans to continue optimizing its business strategy to adapt to the changing business environment[33] - The group plans to adopt digital transformation strategies to enhance operational efficiency and better understand consumer preferences[50] - The group will continue to expand product diversity to meet the preferences of different customer segments[50] Shareholder Information - The company did not declare an interim dividend for the six months ended September 30, 2025, consistent with the previous year[23] - The company has maintained a public float of at least 25% of its total issued shares throughout the period[57] - The company has not granted any stock options under the stock option plan since its adoption, resulting in no unexercised stock options as of September 30, 2025[51] - There were no repurchases of listed securities during the period, nor were there any purchases or sales of such securities by the company or its subsidiaries[52] - As of September 30, 2025, the company did not hold any treasury shares[53] - The board expresses gratitude to shareholders, business partners, and customers for their continued support[60]
澳至尊(02031) - 2026 - 中期业绩